Biological Link Identified Between Heavy Weed Use And Psychosis

Follow Drugslib on

Medically reviewed by Carmen Pope, BPharm. Last updated on April 21, 2025.

By Dennis Thompson HealthDay Reporter

MONDAY, April 21, 2025 -- There’s a biological reason why heavy weed users are at increased risk of psychosis, a new study says.

People with cannabis use disorder have higher levels of the hormone dopamine in the same region of the brain tied to psychosis, brain imaging scans have revealed.

“We now have evidence that shows a straight line linking cannabis with dopamine and psychosis that has never been shown before, and it's crucial that clinicians, patients, and families work together to break this line,” said senior researcher Dr. Lena Palaniyappan in a news release. He's an adjunct professor at Western University’s Schulich Medicine & Dentistry in Ontario, Canada.

Dopamine is an important neurotransmitter that helps the brain process motivation, mood, learning and motor control, researchers said in background notes.

“Excess levels of dopamine can disrupt normal brain processes and may increase the risk of psychosis, particularly in individuals who are already vulnerable,” study co-author Betsy Schaefer said in a news release. She's a senior manager of clinical research operations with the London Health Sciences Center Research Institute in Ontario.

Canada legalized recreational weed use six years ago, and concerns have grown since then that heavy use could cause psychotic episodes, researchers said in background notes.

For the study, researchers used a sophisticated MRI technique to track a substance called neuromelanin in the brains of 25 people with cannabis use disorder and 36 people without the disorder.

Deposits of neuromelanin accumulate over time in people’s brains if there’s too much dopamine, showing up as black spots on MRI scans, researchers said. These deposits can help identify brain regions that are being overly affected by dopamine.

“In people partaking in excess cannabis use, those spots are blacker than what they should be for their age compared to healthy individuals,” Palaniyappan said. “This indicates they have high levels of dopamine, and in some cases are showing pigments someone 10 years older would have.”

Specifically, results indicated “an increase of blacker spots in a particular region of the midbrain associated with psychosis — the substantia nigra and ventral tegmental areas,” researcher Ali Khan, an assistant professor at Western University, said in a news release.

“This increase was seen in those with cannabis use disorder regardless of whether they have first-episode schizophrenia,” Khan added.

The study’s results should be used to counsel weed users about the drug’s potential effects, particularly if they are younger, experts said.

“I think this research really helps to provide evidence, or the smoking gun, of what we're seeing clinically and provides clues as to why exposure to cannabis is causing brain changes linked to psychosis,” Dr. Julie Richard, a psychiatrist and physician lead of LHSC's Prevention and Early Intervention Program for Psychosis, said in a news release.

“In the last several years since legalization, we're seeing adolescents who have two or three brief cannabis-induced episodes of psychosis and then have a much more major episode,” added Richard, who was not involved in the research. “So, we're trying to counsel adolescents within that first episode that they're pushing their brain towards a major episode and show them the areas in the brain that are impacted.”

The new study appears in JAMA Psychiatry.

Sources

  • University of Western Ontario, news release, April 9, 2025

    • Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

    Source: HealthDay

    Posted : 2025-04-22 00:00

    Read more

    Disclaimer

    Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

    The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

    Popular Keywords